Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or
refractory PTCL patients. Patients will be treated with the combination of lenalidomide and
gemcitabine until disease progression, intolerable toxicity, or patient withdrawal.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital National Cheng-Kung University Hospital National Taiwan University Hospital